.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.

Richard B. Lipton

Vorsitz

08.12.2022
09:45 – 10:45
Plenary and EHF session
New guidelines: Round table discussion
Strauss 2-3

Invited speaker

08.12.2022
17:45 – 18:05 15 Min. 5 Min.
Invited lecture
The interictal state of headache

Vortrag

08.12.2022
18:55 – 18:56 1 Min. 0 Min.
On Demand
The interictal state of headache
09.12.2022
15:55 – 16:00 3 Min. 2 Min.
ePoster
P143
Effect of atogepant on the Activity Impairment in Migraine–Diary and Work Productivity and Activity Impairment Questionnaire in a 12-week, double-blind, randomized, phase 3 (PROGRESS) trial for preventive treatment of chronic migraine (CM)
Migraine

Weitere Beteiligungen

09.12.2022
15:30 – 15:35 3 Min. 2 Min.
ePoster
P115
Rimegepant for the Acute Treatment of Migraine: Subgroup Analyses From 3 Phase 3 Clinical Trials by Triptan Treatment Experience
CGRP inhibitors in the clinic, Migraine
09.12.2022
15:35 – 15:40 3 Min. 2 Min.
ePoster
P103
Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial
Migraine
09.12.2022
15:35 – 15:40 3 Min. 2 Min.
ePoster
P243
Characterizing Neck Pain With Headache in People With and Without Migraine: Results From the Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) Study
Epidemiology
09.12.2022
15:40 – 15:45 3 Min. 2 Min.
ePoster
P104
A Phase 2/3 Open-label, Long-term, Safety Trial of Zavegepant 10 mg Nasal Spray for the Acute Treatment of Migraine
CGRP inhibitors in the clinic, Migraine
09.12.2022
15:40 – 15:45 3 Min. 2 Min.
ePoster
P122
Oral Rimegepant 75 mg is Safe and Well Tolerated in Adults With Migraine and Cardiovascular Risk Factors: Results of a Multicenter, Long-Term, Open-Label Safety Study
CGRP inhibitors in the clinic, Migraine
09.12.2022
15:45 – 15:50 3 Min. 2 Min.
ePoster
P105
Sustained Response to Atogepant in Individuals with Episodic Migraine: Post Hoc Analyses of 12- and 52-Week Phase 3 Trials
Migraine
09.12.2022
15:45 – 15:50 3 Min. 2 Min.
ePoster
P123
Medication Preference, Satisfaction, and Clinical Improvement Among Adults Receiving Long-Term Treatment With Rimegepant for Migraine
CGRP inhibitors in the clinic, Migraine
09.12.2022
15:50 – 15:55 3 Min. 2 Min.
ePoster
P142
Effect of atogepant on Migraine-Specific Quality of Life Questionnaire and Headache Impact Test-6 in a 12-week, double-blind, randomized, phase 3 (PROGRESS) trial for preventive treatment of chronic migraine (CM)
Migraine
09.12.2022
15:50 – 15:55 3 Min. 2 Min.
ePoster
P124
Characterizing gaps in preventive treatment of migraine: global results from the CaMEO-International study
Migraine
09.12.2022
15:55 – 16:00 3 Min. 2 Min.
ePoster
P143
Effect of atogepant on the Activity Impairment in Migraine–Diary and Work Productivity and Activity Impairment Questionnaire in a 12-week, double-blind, randomized, phase 3 (PROGRESS) trial for preventive treatment of chronic migraine (CM)
Migraine
09.12.2022
15:55 – 16:00 3 Min. 2 Min.
ePoster
P177
Iprazochrome and codeine – unlikely winners in migraine treatment in Poland. Targeting areas for improvement in migraine treatment (results from Migraine in Poland - a nationwide cross-sectional survey)
Data science in research and digital medicine, Migraine
09.12.2022
16:10 – 16:15 3 Min. 2 Min.
ePoster
P110
Subsequent Response to Atogepant in Individuals with Episodic Migraine after an Initial Inadequate Response: Post Hoc Analysis of a 12-week Phase 3 Trial
Migraine
09.12.2022
16:35 – 16:40 3 Min. 2 Min.
ePoster
P153
Prevalence of sinonasal symptoms in migraine without aura (results from Migraine in Poland - a nationwide cross-sectional survey)
Migraine
09.12.2022
16:40 – 16:45 3 Min. 2 Min.
ePoster
P117
Treatment Responder Rates of Oral Atogepant for the Preventive Treatment of Chronic Migraine: Results From the PROGRESS Trial
Migraine
09.12.2022
16:40 – 16:45 3 Min. 2 Min.
ePoster
P149
Safety and Tolerability of Rimegepant Every Other Day for Preventive Treatment of Migraine Plus As-Needed for Acute Treatment of Migraine: Results from A 52-Week, Open-Label Extension Study
CGRP inhibitors in the clinic, Migraine
09.12.2022
16:45 – 16:50 3 Min. 2 Min.
ePoster
P118
Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) Study: methods and global findings for diagnosis rates and care
Migraine
09.12.2022
16:45 – 16:50 3 Min. 2 Min.
ePoster
P148
Effects of Rimegepant 75 mg on Monthly Migraine Days: a 52-Week, Open-Label Extension Study
CGRP inhibitors in the clinic, Migraine
09.12.2022
16:50 – 16:55 3 Min. 2 Min.
ePoster
P136a
Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial
CGRP inhibitors in the clinic, Migraine
09.12.2022
16:55 – 17:00 3 Min. 2 Min.
ePoster
P120
Monthly Migraine Days, Acute Medication Use Days, and Migraine-Specific Quality of Life in Responders to Atogepant: A Post Hoc Analysis
Migraine